Introduction
Gastro-oesophageal reflux disease refers to the abnormal exposure of the oesophageal mucosa to gastric contents, resulting in a spectrum of conditions. Symptoms of heartburn or acid regurgitation aVect 21-44% of the adult population on a monthly basis. [1] [2] [3] Oesophagitis is less prevalent, and is reported to occur in up to 2% of individuals. 4 5 Symptoms have been shown to have a specificity of 85-95% and sensitivity of 6-39%. 6 Patients with GORD frequently present with atypical symptoms; up to 50% of endoscopically diagnosed cases of oesophagitis present with symptoms other than heartburn or acid regurgitation. [7] [8] [9] In addition GORD is the underlying diagnosis in 2-15% of subjects undergoing investigation for dyspepsia. Accurate diagnosis of GORD can be diYcult with currently accepted criteria including symptoms of heartburn and/or acid regurgitation, improvement with proton pump inhibitor (PPI) treatment, 24 hour oesophageal pH assessment, and/or histological evidence of oesophagitis. Long term sequelae include benign strictures, Barrett's oesophagus, and adenocarcinoma.
Pathophysiological mechanisms described include abnormal transient relaxation of the lower oesophageal sphincter (TLOSR), [10] [11] [12] [13] [14] impaired oesophageal motility, 15 delayed gastric emptying, 16 17 impaired mucosal defences, 18 19 toxic nature of refluxed material (acid, bile), [20] [21] [22] [23] [24] and the presence of hiatus hernia. Although it would appear that GORD is a multifactorial condition predominantly related to abnormal upper gastrointestinal motility, recent interest has focused on the relation between Helicobacter pylori infection and GORD.
H pylori and the aetiology of GORD H pylori is a common infection, responsible for a variety of gastroduodenal pathology, duodenal and gastric ulcer, mucosa associated lymphoid tissue (MALT) lymphoma, and gastric carcinoma. The eVects of H pylori infection on the pathophysiological mechanisms involved in the aetiology of GORD have been examined. H pylori infection has been shown to produce an increase in basal and stimulated gastric acid output through a number of mechanisms, including gastrin, somatostatin, and inflammatory mediators, and this phenomenon of increased acid output has been shown to occur in asymptomatic cases as well as those with peptic ulcer disease and nonulcer dyspepsia. [25] [26] [27] [28] [29] [30] [31] [32] Increased acid secretion as a result of H pylori infection is a plausible aetiological mechanism of GORD in a subset of cases, supported by the observation that patients with duodenal ulceration are more likely to suVer from reflux oesophagitis. 33 However, H pylori colonisation of the gastric mucosa may result in hypochlorhydria as seen in individuals with a diVuse gastritis and gastric atrophy. 34 Patients with this pattern of disease seem to be at less risk of developing GORD than controls. 35 36 There is evidence to associate H pylori infection with both the development of hypochlorhydria and increased acid secretion, depending on the inflammatory response induced. As a result, the eVect of H pylori infection on the development of GORD is similarly contradictory.
Delayed gastric emptying has been reported in association with GORD development. Results of studies exploring the eVect of H pylori on gastric emptying are variable. Several groups have reported no diVerence between H pylori positive and negative subjects. [37] [38] [39] Other groups have shown abnormal antroduodenal motility in patients with GORD and H pylori and delayed gastric emptying in patients with antral predominant gastritis, with or without H pylori infection. [40] [41] [42] There is no clear evidence to associate H pylori infection with a definite dysfunction of gastric emptying and it is unlikely to be a major aetiological factor linking H pylori and GORD. It has been postulated that H pylori colonisation of the gastric cardia may result, through inflammatory mediators and vagal stimulation, in increased TLOSR episodes, hence increasing the likelihood of GORD development. [42] [43] [44] Several groups are investigating the role of carditis with respect to GORD but as yet there is no clear evidence to support this hypothesis.
Epidemiology
Epidemiological studies have in general found little or no association between H pylori infection and GORD (table 1), similar infection rates being reported in patients with GORD and in controls. [45] [46] [47] [48] [49] [50] [51] Some groups have reported a lower incidence of H pylori infection in individuals with GORD and have surmised that infection in some way reduces an individual's risk of reflux oesophagitis. 35 52-54 The observation that H pylori infection was negatively associated with the severity of oesophagitis has added weight to the theory of a protective role for H pylori in GORD. 55 56 However, there is evidence to the contrary. 57 More recently the nature of the infecting organism has been examined. To date three groups have shown that cagA positive infecting strains reduce the risk of both GORD and its complications, including Barrett's oesophagus and oesophageal and cardia carcinoma. 53 58 59 Infection with cagA positive strains of H pylori is associated with a more severe mucosal inflammation in the corpus and antrum, potentiating the risk of developing gastric atrophy and achlorhydria. [60] [61] [62] Such mechanisms have been suggested to explain the negative association between cagA positive strains and GORD. In addition an increased density of infection, associated with virulent infecting strains, may result in an increased production of ammonia, thus potentiating the eVects of PPIs. 63 The fact that virulent strains are responsible for 80-100% of duodenal ulcers and are associated with an increase in acid production seems contradictory. 64 Yet it is known that a history of peptic ulcer is associated with a reduced risk of proximal and distal gastric cancers. 65 With regard to Barrett's oesophagus the majority of studies have again found no association with H pylori. 66 67 Henihan et al have shown a positive correlation between the severity of chronic inflammation in Barrett's oesophagus and H pylori. The possible mechanisms underlying this observation are unknown.
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Carditis, H pylori, and GORD The gastric cardia is the most proximal portion of the stomach, occupying a small zone just distal to the oesophagogastric junction. Under normal circumstances, it comprises tightly packed mucus secreting cells and is devoid of inflammatory cells. Recent interest has focused on carditis, as a possible marker or consequence of GORD or as a possible extension of H pylori induced pangastritis.
Carditis has been reported to be a sensitive marker of GORD. Oberg et al have revealed a positive association between carditis and GORD, as determined by a 24 hour ambulatory pH oesophageal probe assessment. 69 This study did not examine the role of H pylori infection. Others disagree, and have reported that carditis is a manifestation of extensive H pylori colonisation and is independent of oesophagitis. [70] [71] [72] The incidence of proximal gastric cancers like that of oesophageal adenocarcinoma is increasing, 73 whereas that of H pylori infection and distal gastric cancer is falling. Barrett's oesophagus, a consequence of GORD, is a risk factor for the development of oesophageal adenocarcinoma with known premalignant histological markers including intestinal metaplasia and dysplasia. Intestinal metaplasia of the cardia may similarly be a marker of malignant potential though it is not known whether it arises as a long term consequence of GORD or as a result of H pylori infection and associated pangastritis. Consideration of the malignant potential of intestinal metaplasia at the cardia is warranted as it has been identified in proximity to adenocarcinomas of this region. 74 75 Surprisingly intestinal metaplasia of the cardia has been reported in 5-23% of subjects undergoing routine endoscopy and was found more frequently in controls than in those with either oesophagitis or Barrett's oesophagus. 73 76-78 Correlation with H pylori status and intestinal metaplasia in other regions of the stomach is lacking; however, two studies reported to date have found a positive Walker and colleagues 47 Cheng and colleagues 48 Newton and colleagues 49 Befrits and colleagues 50 Liston and colleagues 51 
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Werdmuller and LoVeld 52 Vicari and colleagues 53 Ohara and colleagues 35 Haruma and colleagues 54 79 80 and H pylori status but not to GORD (table 2) . Whether or not individuals on long term PPIs are at an increased risk, as reported for distal intestinal metaplasia, and whether this is a confounding factor is unknown. Assessment of the malignant potential of intestinal metaplasia of the cardia will require further study and its association with H pylori infection confirmed as the results may change current management strategies.
Severity of GORD and H pylori

H pylori eradication and GORD
The indications for H pylori eradication treatment have been broadened in recent years to include several conditions, not only peptic ulceration but also MALT lymphoma, early gastric cancer, and non-ulcer dyspepsia. 81 82 The European consensus guidelines considered the role of eradication treatment in patients with GORD on long term treatment with PPIs. Recent publications have implicated concomitant PPI treatment and H pylori infection with the accelerated development of atrophic gastritis and increased epithelial cell proliferation. [83] [84] [85] [86] Kuipers and colleagues 83 studied 59 H pylori positive subjects treated with either omeprazole or fundoplication for a mean follow up of five years. Thirty one per cent treated with a PPI versus only 5% treated surgically developed atrophic gastritis. Atrophic gastritis is considered a risk factor for the subsequent development of gastric carcinoma. The situation is not clear cut as a recent study by Lundell et al, involving a randomised trial with a three year follow up, showed no increased risk of atrophic gastritis in H pylori positive subjects taking PPIs compared with controls. 86 The observation that PPIs are more eVective in H pylori positive individuals has also brought the policy of prescribing eradication treatment in this setting into question. 87 88 Most reports do suggest that H pylori infection and PPI treatment increases an individual's risk of developing gastric atrophy and as such the benefits of eradication treatment probably outweigh the possible drawbacks.
The successful eradication of H pylori infection in cases of duodenal ulcer has been recently reported to be associated with the subsequent development of GORD. 89 There are two possible explanations: either H pylori infection is protective and eradication induces GORD, or successful treatment with possible alterations in lifestyle, unmasks pre-existing or a propensity for GORD. 90 GORD has been reported to develop in 9-63% of patients following successful H pylori treatment. 91 92 However, up to 20% of patients with duodenal ulcer have pre-existing GORD on initial presentation. 93 With such a high incidence of concomitant disease and an associated increased risk of GORD development with age, it is unlikely that GORD arises de novo in patients with peptic ulcer simply as a result of H pylori eradication and healing of corpus gastritis with an associated return to normal acid secretion. 94 95 More prospective long term follow up studies are again required to clarify this issue.
Conclusion
H pylori infection does not seem to play a causal role in GORD, based on available epidemiological data. Despite this the eVect of H pylori infection on the eYcacy of acid suppressants, the gold standard treatment for GORD, as well as the possible long term effects of both infection and GORD require practitioners to address the issue of whether or not to test for H pylori in patients with GORD and if present whether eradication treatment should be prescribed. The Maastricht consensus report considered this issue and advised, on the basis of supportive evidence, that H pylori treatment should be given to patients with GORD requiring long term acid suppression. The Canadian consensus report does not currently support this management strategy, as there is a need for additional supportive evidence to link H pylori infection and the long term use of PPIs with the development of gastric atrophy.
Reports of de novo GORD development in patients after successful treatment of H pylori associated duodenal ulceration also raise management issues. The possible development of GORD is unlikely to alter the strong indication for H pylori eradication in patients with duodenal ulceration but may enable clinicians to inform patients prior to treatment or select an at risk group. 23 Yes N/A Hirota and colleagues 77 
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